Compare Amylx Pharmaceuticals Inc (AMLX) vs Cloudflare Inc (NET) Price & Performance

AMLX trades at $17.77, down 3.32% today, with a bullish technical signal from moving averages and strong analyst support. The company is in a pivotal phase with key Phase 3 data for avexitide expected in Q3 2026, targeting a potential 2027 launch. Financially, it shows significant losses with negative ROE and ROA, but cash flow from financing activities provides runway. Recent news highlights clinical progress and conference presentations, alongside ongoing class action settlement discussions.

The outlook hinges on successful clinical trial outcomes, particularly avexitide's Phase 3 readout, which could drive substantial upside toward the $30.50 consensus price target. However, high execution risk, persistent cash burn, and legal overhangs pose threats to near-term stability. Investor sentiment remains cautiously optimistic given the 90.9% buy rating from analysts, but the stock is speculative until profitability milestones are achieved.

Cloudflare (NET) trades at $268.40, down 2.61% over 24 hours but remains near recent highs. The stock shows strong technical momentum with bullish moving averages and recent analyst upgrades. Fundamentally, revenue grew to $2.17 billion in 2025, though net income remains negative at -$102 million. Recent news highlights Cloudflare's strategic pivot toward AI infrastructure, including a research pilot with OpenAI announced July 8, 2026.

Outlook remains optimistic due to AI-driven growth potential and consistent earnings beats, but high valuation multiples (P/S 40.36) and negative profitability pose risks. Analyst consensus is strongly bullish with a $250.33 price target, though competition and execution challenges could pressure shareholder returns.